Federica Galimberti has a solid multidisciplinary background acquired during her Master’s degree in Pharmaceutical Chemistry and Technology (University of Milan, 2016). During her 3-year PhD program in Experimental and Clinical Pharmacological Sciences at the Department of Pharmacological and Biomolecular Sciences (University of Milan, 2016-2019), she expanded her knowledge on pharmacoepidemiology and pharmaco-utilization, in the frame of prevention of cardiovascular diseases and associated risk factors. In details, she gained expertise in the design, conduction and monitoring of drug use and safety profile studies, and prescribing appropriateness studies, mainly through healthcare utilization databases analyses. The expertise in analysing data acquired during her PhD experience led her to spend a period at Cardiovascular Epidemiology Unit of University of Cambridge, where she enhanced her knowledge on genomic and pharmacogenomic topic related to the cardiovascular system, and experienced the conduction of studies based on the principles of Mendelian randomization to identify risk factors that have both a causal and a cumulative effect of the risk of cardiovascular disease, and to model “naturally randomized trials” that attempt to frame and answer clinical questions to fill evidence gaps when an actual clinical trial would be impractical or impossible to conduct.